This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Osmol Therapeutics

Profile

Osmol is a development stage biopharma company advancing technology licensed from Yale University to prevent chemotherapy induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with a number of common chemotherapies including taxanes, the most widely used breast cancer treatment. There are no approved treatments for CIPN, leaving oncologist’s only option to reduce the dose or length of chemotherapy treatment. Osmol’s initial focus is in breast cancer where up to 80% of patients develop CIPN.